KIT and gastrointestinal stromal tumor: Further, after clinical progression of advanced GIST on imatinib, the clinical benefit of sunitinib and regorafenib is limited, with median time to progression of 6 months or less.16,17 Our previous studies have shown that some but not all imatinib-resistant KIT-mutations respond to sunitinib.